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Multistage and transmission-blocking targeted
antimalarials discovered from the open-source
MMV Pandemic Response Box
Janette Reader1, Mariëtte E. van der Watt1, Dale Taylor2, Claire Le Manach 2, Nimisha Mittal3, Sabine Ottilie3,
Anjo Theron 4, Phanankosi Moyo 1, Erica Erlank5, Luisa Nardini 5, Nelius Venter5, Sonja Lauterbach 6,
Belinda Bezuidenhout6, Andre Horatscheck 2, Ashleigh van Heerden 1, Natalie J. Spillman 7,
Anne N. Cowell3, Jessica Connacher1, Daniel Opperman1, Lindsey M. Orchard 8, Manuel Llinás 8,9,
Eva S. Istvan 7, Daniel E. Goldberg 7, Grant A. Boyle2, David Calvo 10, Dalu Mancama4,
Theresa L. Coetzer 6, Elizabeth A. Winzeler 3, James Duffy11, Lizette L. Koekemoer 5, Gregory Basarab 2,
Kelly Chibale2,12 & Lyn-Marié Birkholtz 1 ✉

Chemical matter is needed to target the divergent biology associated with the different life
cycle stages of Plasmodium. Here, we report the parallel de novo screening of the Medicines
for Malaria Venture (MMV) Pandemic Response Box against Plasmodium asexual and liver
stage parasites, stage IV/V gametocytes, gametes, oocysts and as endectocides. Unique
chemotypes were identiﬁed with both multistage activity or stage-speciﬁc activity, including
structurally diverse gametocyte-targeted compounds with potent transmission-blocking
activity, such as the JmjC inhibitor ML324 and the antitubercular clinical candidate SQ109.
Mechanistic investigations prove that ML324 prevents histone demethylation, resulting in
aberrant gene expression and death in gametocytes. Moreover, the selection of parasites
resistant to SQ109 implicates the druggable V-type H+-ATPase for the reduced sensitivity.
Our data therefore provides an expansive dataset of compounds that could be redirected for
antimalarial development and also point towards proteins that can be targeted in multiple
parasite life cycle stages.
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alaria treatment solely relies on drugs that target the
parasite, but current treatment options have a ﬁnite
lifespan due to resistance development. Moreover, while
current antimalarials are curative of asexual blood stage parasitaemia and associated malaria symptoms, they cannot all be used
prophylactically and typically do not effectively block transmission. The inability to block transmission is limiting malaria
elimination strategies, which requires chemotypes that block
human-to-mosquito (gametocyte and gametes) and mosquito-tohuman (sporozoites and liver schizonts) transmission.
As few as 100 sporozoites are able to initiate an infection after
migrating to the liver for exoerythrocytic schizogony. The subsequent release of thousands of daughter cells, which in turn infect
erythrocytes, initiates the extensive population expansion that
occurs during asexual replication. A minor proportion (~1%)1 of
the proliferating asexual parasites will undergo sexual differentiation to form mature stage V gametocytes, a 10–14-day process in the most virulent parasite Plasmodium falciparum. Only
~103 of these falciform-shaped mature gametocytes are taken up
by the next feeding mosquito to transform into male and female
gametes in the mosquito’s midgut2. Fertilization results in zygote
development, and a motile ookinete that passes through the
midgut wall forms an oocyst from which sporozoites develop,
making the mosquito infectious.
The sporozoite and gametocyte population bottlenecks3 have
been the basis of enticing arguments for developing chemotypes
able to target them. However, most compounds able to kill
asexual parasites are either ineffective in preventing infection
and/or blocking transmission or are compromised by resistance
development (e.g. antifolates active as prophylactics) or toxicity
concerns (e.g. primaquine targeting gametocytes with associated
haemolytic toxicity in glucose-6-phosphate dehydrogenasedeﬁcient patients). Patients treated with current antimalarials
(or asymptomatic carriers) may harbour enough gametocytes to
be transmitted to mosquitoes and sustain the malaria burden. The
development of gametocyte-targeted transmission-blocking
compounds is therefore essential for a complete strategy directed
at eliminating malaria.
Phenotypic screens of millions of compounds have successfully
identiﬁed antimalarial hits to populate the drug discovery pipeline.
However, the majority of these screens assessed activity against
asexual blood stage parasites as the primary ﬁlter, and hits were
only proﬁled thereafter for activity against additional life cycle
stages. While this strategy can identify compounds targeting two
or more life cycle stages, it does not allow de novo discovery of
compounds with selective activity against speciﬁc life cycle stages,
such as gametocytes. Parallel screening against multiple life cycle
stages would best identify such compounds and rely on selective
and predictive assays for gametocytocidal activity4, transmissionblocking5,6, and hepatic development7. Recently, parallel screening
of diversity sets has resulted in reports of such stage-speciﬁc
compounds7–10, with the beneﬁt that divergent biology associated
with the different life cycle states can be targeted5,6,11.
In this work, we describe the parallel screen of the Medicines
for Malaria Venture (MMV) Pandemic Response Box (PRB) on
Plasmodium asexual stage parasites, liver stage parasites, mature
(stage IV/V) gametocytes, male gametes and oocysts (Fig. 1), as
well as mosquito endectocide activity. The MMV, in partnership
with the Drugs for Neglected Disease Initiative, assembled the
PRB as a collection of 400 drug-like compounds stratiﬁed by
antibacterial, antiviral or antifungal activity (201, 153, and 46
compounds, respectively), with some compounds having antineoplastic activity. The unique and diverse nature of the compounds in the PRB allow one to explore and target the unique
biology in the parasite’s different life cycle stages to identify
chemical starting points for antimalarial development. All screens
2

were performed on the human parasite P. falciparum, except for
the liver stages, where the established Plasmodium berghei assay
was used12,13. Hit selection and progression of compounds in our
screening cascade was not biased towards activity on any single
life cycle stage, allowing the discovery of multistage-active scaffolds and those with stage-speciﬁc activity. Importantly, we report
the proﬁling of a subset of compounds as transmission-blocking
molecules that would not have been identiﬁed in a test cascade
that began solely with an asexual blood stage assay. Four
transmission-targeted leads include compounds that are chemically tractable, have favourable physicochemical properties and
operate by previously undescribed modes of action, making them
amenable to development as transmission-blocking antimalarials.
Results
Parallel screening of the PRB reveals hits against multiple life
cycle stages. To identify active compounds against different stages
of the Plasmodium life cycle (irrespective of their activity against
the other life cycle stages), the PRB was screened in parallel against
PfNF54 asexual parasites and stage IV/V gametocytes and P.
berghei liver stage (Fig. 1). The PfNF54 stage IV/V gametocyte
data were orthogonally validated on three independent gametocyte
assays to conﬁrm that hit selection (compounds active on at least
two platforms) was independent of assay readout4. Hits were
identiﬁed with a relatively lenient but inclusive cut-off of ≥50%
inhibition at 2 μM for asexual stages (within 4 S.D.) and 5 μM for
gametocytes and liver stages (both within 3 S.D.). Asexual stage
activity was conﬁrmed against drug-resistant PfDd2 asexual
parasites. Cytotoxicity ﬁltering was applied after evaluation of the
50% inhibitory concentration (IC50), and transmission-blocking
potential of compounds with gametocytocidal activity was conﬁrmed by inhibition of male gamete exﬂagellation and in a standard membrane feeding assay (SMFA). Assay reproducibility
indicators are provided in Supplementary Table 1.
An 18% hit rate was obtained against PfNF54 asexual parasites,
12% against PfNF54 stage IV/V gametocytes and 11% against
liver stage parasites (Fig. 2a, Supplementary Data 1). Although a
number of compounds showed activity against all these life cycle
stages, stage-speciﬁc differentiation was evident, as exempliﬁed by
the overrepresentation of antifungal compounds in the hit pool
for stage IV/V gametocytes compared to asexual parasites
(Fig. 2b). The remaining hits reﬂect the distribution of the
compounds in the PRB, with the highest number of hits classiﬁed
as antibacterials followed by antivirals. The latter seemed to be
more potent (as a percentage of the hits) on PfNF54 stage IV/V
gametocytes relative to PfNF54 asexual parasites. Only four
compounds showed marked toxicity against Chinese hamster
ovarian (CHO) cells (<50% viability at 2 μM, supplementary
Fig. 1). Superimposition of the PRB chemical space on current
antimalarial drugs within the launched drugs chemical space
(Supplementary Fig. 2) indicates little overlap.
Based on the target indicators/biological pathway descriptors
for the PRB compounds in other diseases, PfNF54 asexual hits
were enriched for inhibitors of kinases, CYP450, energy
metabolism and DNA synthesis. Inhibitors of dihydrofolate
reductase (DHFR, antifolates), dihydroorotate dehydrogenase,
proton pumps and topoisomerase were exclusive hits for PfNF54
asexual and liver stage parasites. Compounds with both PfNF54
asexual and gametocyte activity include antithrombotics, protease
inhibitors, sphingosine-1-phosphate receptor modulators and
compounds affecting redox homoeostasis, whereas inhibitors of
the mycobacterial MmpL3 (mycobacterial membrane protein
large 3) and ion channels were predominant in gametocyte hits
(Fig. 2c). Chemical classes highly represented in the hit pool
include quinolines, benzamides/benzoids and azoles.
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Fig. 1 Screening cascade of the MMV Pandemic Response Box for activity against multiple life cycle stages of Plasmodium. The 400 compounds in the
PRB were screened in a primary assay against drug-sensitive (NF54) P. falciparum asexual blood stages (ABS, at 2 and 20 µM) and mature gametocytes
(stage IV/V, GC, 1 and 5 µM) and P. berghei liver stages (5 µM). Hits were selected based on ≥50% inhibition at speciﬁc concentrations as indicated.
The criteria for each decision point are indicated followed by the number of compounds that passed the criteria. Compounds were additionally evaluated in
dose response on drug-resistant asexual Dd2 parasites (chloroquine, pyrimethamine and meﬂoquine resistant). * = the potent ABS compounds (IC50 < 2
µM), after removing toxic compounds and eliminating overlapping compounds between PfNF54 and PfDd2, amount to 28 compounds in total. IC50 50%
inhibitory concentration, pLDH parasite lactate dehydrogenase assay, PB PrestoBlue® assay, ATP ATP viability assay, Luc luciferase reporter lines assays,
Pf Plasmodium falciparum, Pb Plasmodium berghei, S.I. selectivity index, CHO Chinese hamster ovarian cells, HepG2 hepatocellular carcinoma line, TBA
transmission-blocking activity, TRA transmission-reducing activity, SMFA standard membrane feeding assay. Parasite drawings were modiﬁed from freely
available images (https://smart.servier.com/), under a Creative Commons Attribution 3.0 Unported Licence.

Multistage-active compounds. All hit compounds were counterscreened against either CHO or HepG2 mammalian cells to remove
cytotoxic compounds (Supplementary Data 2) from further consideration for characterization as antimalarials. Of the 72 PRB hits
against asexual parasites, all activities were conﬁrmed on rescreening, and of these, 28 compounds passed a further stringent
cut-off with IC50 values <2 μM (Fig. 2a and Supplementary Data 2),
with 16 compounds exclusively active against the asexual stages
(Fig. 3a). Of the 51 hits against PfNF54 stage IV/V gametocytes, 18
compounds had IC50 values <2 μM. Eight shared activity against
asexual stages but ten had gametocyte stage-speciﬁc activity (Fig. 3a).
Only six compounds showed activity against P. berghei liver stages
(<2 μM). Notably, two compounds showed pan-reactivity against
all life cycle stages: the peptidomimetic antitumour agent
MMV1557856 (Birinapant, a SMAC-mimetic inhibitor of apoptosis
proteins (IAPs))14 and the imidazoquinoline antitumour agent
MMV1580483 (AZD-0156, a Ataxia Telangiectasia Mutated kinase
inhibitor) (Fig. 3b and Supplementary Table 2).
Asexual-speciﬁc chemotypes. Encouragingly, the 28 compounds
with asexual parasite activity (Supplementary Data 2) included the
known antimalarial compounds chloroquine (MMV000008) and

tafenoquine (MMV000043), which were both present in the PRB
and showed IC50s comparable to those previously reported6
(30 and 940 nM, respectively), validating the screening process
(Fig. 4). The most potent of the 28 compounds was an
antibacterial diaminopyridine propargyl-linked antifolate15,
MMV1580844 (IC50 = 0.0017 μM), which targets DHFR in
mammalian and yeast cells16,17, and was active against P. berghei
liver stages (0.004 μM) but not PfNF54 stage IV/V gametocytes,
supporting previous reports that inhibition of Plasmodium DHFR
is effective in asexual and liver stages6. MMV1580844 had a
pronounced (63-fold) loss of activity against pyrimethamineresistant PfDd2. By contrast, the quinazoline antifolate trimetrexate (MMV1580173, derived from methotrexate) was potently
active only against PfDd2 (IC50 = 0.108 μM) as well as P. berghei
liver stages (IC50 = 0.0005 μM), in both instances with >10-fold
selectivity towards the parasite vs CHO cells.
Importantly, the majority (13/16) of the asexual-speciﬁc
compounds had not been previously reported with antiplasmodial activity nor do they show structural similarity to any
antiplasmodial (Fig. 4 and Supplementary Fig. 2), providing
chemotypes for further evaluation. Interestingly, the majority of the
asexual-speciﬁc compounds are classiﬁed as antibacterials and
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include two kinase inhibitors, MMV1593539 (IC50 = 0.686 μM), a
pyruvate kinase inhibitor, and MMV1580482 (URMC-099-C,
IC50 = 1.3 μM), a mixed lineage kinase 3 (MLK3) inhibitor.
Additionally, there is pibenzimol (MMV020752, IC50 = 0.149 μM),
a disrupter of DNA replication, and MMV019724 (IC50 = 1.67 μM),
an antiviral lactate dehydrogenase inhibitor.
4

Liver stage activity is associated with asexual parasite activity.
Six dual-stage compounds (asexual blood stage and P. berghei
liver stage activity ≤2 μM) were identiﬁed in the PRB, marking
them as having prophylactic potential (IC50 range from 0.0005 to
1.72 μM, Fig. 4). These compounds include not only previously
described antifolates (MMV1580173 and MMV1580844) but
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Fig. 2 Primary screening of the PRB for hits against P. falciparum parasites. a Supra-hexagonal maps of all 400 compounds included in the PRB after
analysis on P. falciparum NF54 asexual blood stage parasites, stage IV/V gametocytes, and Pb liver stage. Each hexagon is indicative of a single compound
and the order of the hexagon is the same between the plots. Colours on the heat bar indicate percentage of inhibition of proliferation (asexual blood stage
parasites) or viability (stage IV/V gametocytes) after treatment with each compound at either 2 µM (asexual blood stages) or 5 µM (stage IV/V
gametocytes or liver stages), screened at least in duplicate. The data for the stage IV/V gametocytes are compiled from hits identiﬁed with three different
assay platforms, run in parallel (ATP, PrestoBlue® and luciferase reporter expression) with any hit on any platform included, and where identiﬁed on >2
platforms, the highest value was included. b Proportional distribution of hits (>50% inhibition @ 2 µM for asexual blood stages or 5 µM for stage IV/V
gametocytes and liver stages) based on disease area as deﬁned in the PRB. Bars are delineated to show activity distribution. ABS asexual blood stages, GC
stage IV/V gametocytes, L liver stage. c Stratiﬁcation of hits from a (>50% inhibition @ 2 µM for asexual blood stages or 5 µM for stage IV/V gametocytes
and liver stages, screened in duplicate). The number of compounds that could be associated with a speciﬁc biological activity or target indicator is shown.
Protein targets/metabolic pathways were identiﬁed based on the descriptions of compounds with known activity in the PRB in other disease systems. FT
farnesyltransferase inhibitors, GPCR G protein-coupled receptors, S1P sphingosine-1-phosphate receptor modulators, CYP cytochrome inhibitors, ETC
electron transport chain, DHFR dihydrofolate reductase, DHODH dihydroorotate dehydrogenase.
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Fig. 3 Active compounds on multiple stages of Plasmodium development after dose–response evaluation and cytotoxicity ﬁltering. a Venn diagram of
the number of compounds identiﬁed with activity (inhibitory concentration, IC50) below 2 µM, for which no cytotoxicity was identiﬁed on either CHO cells
(>50% viability at 2 µM or selectivity index >10) or HepG2 cells (selectivity index >10). b A total of two compounds with activity against all life cycle
stages tested: Birinapant and AZD-0159. Asexual blood stage activity (ABS) was determined against both drug-sensitive (NF54) and drug-resistant (Dd2)
P. falciparum. GC P. falciparum stage IV/V gametocytes. Toxicity indicated both at CC50 (cytotoxic concentration) against HepG2 cells as well as for
viability of CHO cells remaining after 20 µM treatment. Data are from three independent biological repeats, performed with minimum technical duplicates,
mean ± S.E. 95% conﬁdence intervals on all IC50 values are provided in Supplementary Data 2.

also the ribonucleotide reductase inhibitor MMV1580496
(triapine) and the bacterial methionyl-tRNA synthetase inhibitor
MMV1578884 (REP3123) in addition to the multistage-active
compounds, AZD-0156 and Birinapant.

Unique compounds with stage-speciﬁc activity against IV/V
gametocytes. Eighteen compounds were active (IC50s < 2 μM)
against late-stage gametocytes, as conﬁrmed in at least two of the
three orthogonal assays (ATP, PrestoBlue® or luciferase reporter
assays, Supplementary Data 2). Of these, eight compounds shared
asexual parasite activity, but importantly, ten compounds selectively
inhibited PfNF54 stage IV/V gametocytes (>10-fold difference in
IC50, Fig. 5). The most potent compound was the antineoplastic
epidrug ML32418 (MMV1580488, IC50 = 0.077 μM), and a marked
selection for structurally unrelated inhibitors of G protein-coupled
receptors (GPCRs) and related transmembrane proteins were present (Fig. 5a). This includes MMV1581558 (IC50 = 0.130 μM) and
two MmpL3 inhibitors: the well-characterized 1,2-ethylene diamine
antitubercular clinical candidate SQ10919–21 (MMV687273, IC50 =
0.105 μM) and a rimonabant derivative MMV158084322 (IC50 =
0.108 μM). Two structurally distinct imidazole antifungals also
showed potent activity against gametocytes (Supplementary Fig. 3):

MMV1634491 (IC50 = 0.208 μM) and MMV1634492 (the topical
antifungal eberconazole, IC50 = 0.23 μM).
Gametocytocidal compounds target male gametes. Gametocytocidal hits were validated on male gametes that are generally
more sensitive to compounds23. The majority of compounds (13)
inhibited male gamete exﬂagellation by >60% (2 μM, Fig. 5b), 8 of
which were potent at ≥80% inhibition. The latter included the
gametocyte-targeted compounds MMV1580488 (ML324), the
azole antifungals MMV1634491 and MMV1634492 and the
MmpL3 inhibitor MMV687273 (SQ109), as well as compounds
with additional asexual parasite activity (MMV1580483,
MMV396785, MMV1582495, MMV1578570, MMV1581558).
The gametocytocidal activity was irreversible for all the compounds except MMV1578570 (Supplementary Fig. 4)24. Six
compounds (the epidrug MMV1580488, the two azole antifungals
(MMV1634491, MMV1634492), a quinoline MMV1634399 and
two MmpL3 inhibitors (MMV1580843, MMV687273)) were
directly active on male gametes, implying that shared essential
biology between these stages is being targeted.
Chemotypes with conﬁrmed transmission-blocking activity
(TBA). Transmission-blocking activity was validated by
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Fig. 4 Asexual blood stage active compounds from the PRB in relation to malaria clinical drugs. PRB compounds active against asexual blood stage
(ABS) parasites of P. falciparum. Compounds with inhibitory concentrations (IC50) <2 µM were identiﬁed as hits against either PfNF54 or PfDd2. PRB hits
are represented in the launched drugs chemical space (available within the StarDrop V 6.6 software, beige) in comparison to malaria clinical drugs (blue
dots). Asexual blood stage actives with IC50 values <2 µM are indicated in red, and gametocyte actives and liver stage actives (all at the same cut-off) are
indicated in green and black, respectively, with different dot diameters to highlight compounds active on multiple stages. The 16 asexual-speciﬁc
compounds are labelled with Compound ID, asexual stage IC50 and structure and other compounds of interest just by name and IC50. CQ chloroquine, TQ
tafenoquine.

the mosquito-based SMFA25–27, using an African malaria
vector, Anopheles coluzzii (G3). Transmission-reducing activity
(TRA; reduction in oocyst intensity) and TBA (reduction in
oocyst prevalence) were determined 8–10 days after feeding
female mosquitoes on gametocyte-infected blood, treated with
selected compounds (2 μM, Fig. 5c, Supplementary Fig. 5 and
Supplementary data 3). Total sample size for the control feeds
averaged at 53 mosquitoes, with average oocyst prevalence at 71%
and oocyst intensity of 5.8 oocysts/midgut. The TRA for
MMV000043 (Tafenoquine) at 77% correlates with previous
reports on Anopheles stephensi28, validating assay performance
with A. coluzzii. All the compounds (except for MMV1580853)
reduced TRA by >60% and, remarkably, nine compounds had
≥80% TRA. Four gametocyte-targeted, structurally dissimilar
compounds MMV1006203 (1,1-dioxide 1-Thioﬂavone), the azole
antifungal MMV1634492, a quinoline MMV1634399 and the
GPCR inhibitor MMV1581558 were able to block transmission
(TBA) by ≥60% (MMV1634492 by 79%), associated with a signiﬁcant reduction in oocyst intensity (p < 0.05, Supplementary
Data 3).
6

Endectocide activity. Gametocytocidal compounds were evaluated for their activity as endectocides, killing mosquitoes after
supplied in an uninfected blood meal. However, none of
the compounds produced signiﬁcant mortality (one-way analysis
of variance (ANOVA), p = 0.7005, total DF = 71, n ≥ 2) in the
4-day mortality assay at 2 μM (Supplementary Fig. 6). Rather,
moderate killing (~30%) was observed for the two MmpL3
inhibitors MMV687273 and MMV1580843, the GPCR inhibitor
MMV1581558, AZD-0156 (MMV1580483) and MMV1174026,
marking these compounds with some potential to kill the parasite
and mosquito vector.
Mechanistic explorations of transmission-targeted compounds
MMV1580488 (ML324) and MMV687273 (SQ109). We investigated the potential mechanism of action of the most potent
transmission-targeted compound, ML324, and the antitubercular
clinical candidate SQ109.
ML324, together with another inhibitor JIB-04, was recently
described as active site inhibitors of a recombinantly expressed
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Jumonji-domain containing demethylase (KDM4), jmj3 in
Plasmodium29. Inhibition of Pfjmj3 with JIB-04 results in altered
histone methylation29, aberrant gene expression and ultimately
parasite death. Here we show that ML324 was signiﬁcantly more
potent against late-stage gametocytes compared to early-stage
gametocytes and asexual parasites (Fig. 6a). Mechanistically,
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ML324 treatment signiﬁcantly increased H3K9me3 levels
(a repressive heterochromatin mark in P. falciparum gametocytes)30 in late-stage gametocytes, while not affecting acetylation
(Fig. 6b, p = 0.028, t test, n = 3). This translated to differential
expression of 13% of the genome (Fig. 6c, p < 0.01, >0.5 log2 fold
change (FC) in either direction, Supplementary Data 4), similar to
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Fig. 5 Transmission-blocking activity of active compounds from the PRB against P. falciparum stage IV/V gametocytes, gametes and oocysts.
a Chemical cluster analysis of the gametocyte hit compounds, using the FragFP descriptor and a Tanimoto similarity index >0.50 in OSIRIS DataWarrior v
5.0.0, and network construction with Cytoscape v 3.7.2. Edges were assigned between similar scaffolds and a parent node. Active compounds with IC50
values <2 µM are indicated in green, those with additional activity at the same cut-off on ABS are indicated with hexagons and those with shared activity on
liver stages with black borders. Structures are highlighted for selected compounds. Data are from three independent biological repeats (n = 3), each
performed in technical triplicates, ±S.E. b Nineteen compounds with activity against P. falciparum stage IV/V gametocytes were evaluated for their ability to
inhibit male gamete exﬂagellation. Compounds (2 µM) were used on stage IV/V gametocytes for a 48-h treatment prior to inducing male gamete
exﬂagellation (carry-over format). Data are from three independent biological repeats (n = 3), performed in technical triplicates, mean ± S.E indicated,
except for MMV1633967, MMV1634399 and MMV000043, for which data are from n = 2 biological repeats). Individual data points are indicated in
symbols. c SMFA data for 17 compounds (selected based on >50% inhibition on male gamete exﬂagellation). SMFA was performed by feeding A. coluzzii
mosquitoes with compound-treated gametocyte cultures (48 h treatment at 2 µM). Data are presented as percentage of TRA (transmission-reducing
activity, reduction in oocyst intensity: CiCiTi  100, where i: oocyst number (intensity), C: control and T: treated) from at least three independent biological
repeats (n = 4), performed with technical duplicates, mean ± S.E indicated. Individual data points are indicated in symbols.
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Fig. 6 MMV1580488 (ML324) inhibition of histone demethylation and induction of aberrant gene expression in gametocytes. a Dose–response
analysis of ML324 on asexual parasites (ABS) and early- (stage II/III, EG) or late-stage (LG, stage IV/V) gametocytes on the PrestoBlue® assay. Data are
from three independent biological repeats (n = 3), performed in technical triplicates, mean ± S.E indicated. 95% conﬁdence intervals on each point
indicated as ribbons for each sigmoidal curve. IC50 ABS: 2.06 ± 0.119 µM; IC50 EG: 0.188 ± 0.029 µM; IC50 LG: 0.077 ± 0.001 µM; **p = 0.0036 ABS vs LG;
**p = 0.0052 ABS vs EG, paired, two-tailed t test. b Relative abundance of histone modiﬁcations (anti-H3core, anti-H3K9me3 and anti-H3K9ac) for
gametocytes treated with ML324 (5 µM) for 24 h. Data are from three independent biological repeats (n = 3), performed in technical triplicates, mean ± S.
E indicated. *p = 0.028, paired, two-tailed t test. c Transcriptome analysis of gametocytes treated ML324 (5 µM) for 24 h indicating transcripts with
signiﬁcant differential expression (log2 FC > 0.5 increased (red) or decreased (blue) compared to control untreated parasites). GO annotations on
biological process level indicated for the increased or decreased abundance gene sets (Fisher’s exact test, two-tailed, exact p values provided on ﬁgure per
GO term; gene names indicated in Supplementary Data 4).
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JIB-04 inhibition of Pfjmj329. Despite differences in parasite
stages evaluated for aberrant gene expression proﬁles due to JIB04 or ML324 treatment (asexual vs gametocyte treatments),
several processes were similarly affected by these two inhibitors of
Pfjmj3 (Supplementary Data 4). Comparatively, there is a
complete lack of overlap between aberrant gene expression due
to ML324 treatment and that caused by inhibition of a histone
methyltransferase with BIX-01294 in gametocytes31, implying at
least some conserved and speciﬁc responses associated with
Pfjmj3 inhibition. ML324 treatment of gametocytes caused

repression of known H3K9me3-associated genes involved in cell
adhesion (Fig. 6c)30 and DNA/chromatin-related processes,
including three histone methyltransferases (SET7, 9 and 10),
histone H3 and heterochromatin protein 1. Several Api-AP2
transcription factor family members also showed aberrant
expression under ML324 pressure including Api-AP2-O3 (ookinete associated). Among the transcripts with increased abundance is another jmj family member, jmjC230, and gametocyteassociated proteins gametocyte development 1 (gdv1) and male
gamete gene 1 (mdv1). The lack of removal of heterochromatic
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Fig. 7 Mechanistic investigations of MMV687273 (SQ109). a IC50 for MMV687273 (SQ109) on late-stage gametocytes (LG, stage IV/V), early-stage
gametocytes (EG, stage II/III) or asexual parasites (ABS) tested on the same assay platform (PrestoBlue®) for 48 h drug pressure. Data are from three
independent biological repeats (n = 3), performed in technical triplicates, mean ± S.E indicated. 95% conﬁdence intervals on each point indicated as ribbons
on each sigmoidal curve. IC50 ABS: 1.39 ± 0.090 µM; IC50 EG: 0.383 ± 0.108 µM; IC50 LG: 0.109 ± 0.002 µM; **p = 0.0052 ABS vs LG; *p = 0.036 ABS vs
EG, paired, two-tailed t test. b IC50 for MMV687273 (SQ109) tested on stage IV/V gametocytes after 12, 24 or 48 h drug pressure (PrestoBlue® assay).
Data are from three independent experiments (n = 3), each in triplicate, ±S.E. c The percentage of inhibition of stage IV/V viability under 1 µM pressure
of MMV687273 (SQ109) compared to MMV180402 (2-adamantanamine) or the parent compound ethambutol (MMV687801, S,S-ethambutol and
ethambutol.HCl). Data are from three independent biological repeats (n = 3), in technical duplicates each, mean ± S.E indicated. ***p = 0.0006, **p =
0.0052, paired, two-tailed t test. d Structure of the P. falciparum V-type H+-ATPase subunit A (PfvapA, PF3D7_1311900, cyan in all cases, code Q76NM6
Swiss Model Repository), using the mammalian V-type ATPase from rat brain (6vq6.1) as template. The soluble V1 and membrane-associated Vo domains
of the mammalian complex is indicated. e Top view of the V1 domain, indicating the overlap of PfvapA (cyan) with subunit A of the mammalian complex
(purple) compared to subunit B (turquoise) and f structure of PfvapA alone with side view. Bound ADP is indicated in red, the mutations in PfvapA is as
follows: Q225K in orange, R353K in yellow.

H3K9me3 in ML324-treated parasites therefore results in the
inability of the parasite to prepare for gametogenesis (concurring
with ML324’s efﬁcacy against male gametes, Fig. 5b), since gene
silencing is maintained.
SQ109 showed a signiﬁcant >10-fold selectivity towards late-stage
gametocytes compared to asexual parasites (p = 0.0052, n = 3 paired
t test, Fig. 7a). Since SQ109 is an established inhibitor of MmpL3 in
mycobacteria19–21 with typical rapid action21,32, we evaluated the rate
of gametocytocidal action of SQ109 for 12, 24 and 48 h (Fig. 7b). No
signiﬁcant difference (p = 0.937 and p = 0.558, respectively; one-way
ANOVA, n = 3) was observed in the IC50 values, indicating that the
effect was present already within 12 h of exposure to gametocytes.
Moreover, the activity of SQ109 was similar to the parent compound
S,S-ethambutol.2HCl20 (MMV687801.2HCl), whereas a structurally
related 2-adamantanamine (MMV180402) was inactive (Fig. 7c).
We subsequently evaluated the potential for MmpL3-like targets in
P. falciparum. The parasite’s genome does not predict any direct
homologues to MmpL3 and only two members of the resistancenodulation-division (RND)-superfamily (to which MmpL3 belongs)
are present. This includes a Niemann–Pick type C1-related H+/lipid
symporter (PfNCR1)33. However, treatment of a PfNCR1 knockdown line with SQ109 did not confer any marked loss of activity,
indicating that SQ109 does not likely interact with this protein in
Plasmodium spp. (Supplementary Fig. 7). In an attempt to identify
alternative molecular targets, resistant mutant selection was
performed on P. falciparum 3D7 (A10 clone) under SQ109 pressure.
Stable but low-level resistance (2–3-fold increase in IC50 to SQ109
compared to the parental line) was obtained from two independent
selections. Whole-genome sequencing of two clones from each
selection indicated mutations in the P. falciparum V-type H+ATPase (PfvapA, PF3D7_1311900), at one position each: Q225K and
R353K (Supplementary table 3). These mutations occur in the A
subunit, part of the soluble, ATP-hydrolytic V1 domain of the protein
complex. Structural analysis of PfvapA based on homology (61%
sequence identity) to the mammalian V-type ATPase subunit A
indicated that both mutations fall within the nucleotide-binding
domain of the protein (Fig. 7d–f and Supplementary Fig. 8).
Importantly, the Q225K mutation sits within the conserved
nucleotide binding pocket of the protein and results in a steric clash
with ADP (Fig. 7f), at the catalytic B–A subunit interface,
distinguished from the non-catalytic A–B interface (Fig. 7e). PfvapA
has been shown to be present on the parasite’s plasma membrane
and digestive vacuole34, and inhibition thereof typically results in
parasite death due to disturbance of ATP-dependent H+ efﬂux and
pH regulation35,36.
Discussion
The ability to quickly respond to pandemics has become of
paramount importance, and compound sets like the PRB provide
an essential tool to support rapid screening of diverse druggable
10

compounds for potential repurposing. Indeed, antimalarials have
previously been investigated as antineoplastics37,38 and several
antibiotics and antifungals have previously demonstrated antimalarial activities39,40. Here we screened the PRB across multiple
Plasmodium stages and identiﬁed chemical matter with antimalarial activity not previously described, providing a useful
resource to the research community for drug repurposing as well
as lead matter for drug optimization.
Multistage activity is a preferential attribute for the next generation of antimalarials41, but such compounds are rarely found
in diversity library screens, in large part due to targeted screening
approaches rather than parallel screening in multiple assays. We
identiﬁed two non-cytotoxic multistage-active compounds in the
PRB (Birinapant and AZD-0156) that could point to biological
parsimony of conserved targets in all these stages, essential to the
survival of the parasite such as inhibiting proteins involved in
cellular stress responses by either inducing apoptosis or preventing DNA damage recovery responses. Interestingly, Birinapant preferentially killed Plasmodium-infected hepatocytes by
reducing host cellular IAP42.
The dual-active asexual and liver stage compounds identiﬁed in
the PRB have the potential for prophylactic and chemoprotective
utility (target candidate proﬁle 4 (TCP-4)), in addition to being
chemotherapeutically relevant (target candidate proﬁle 1 (TCP1))41. Though compounds targeting the same parasite protein in
both liver and asexual stages have the associated risk of targetbased resistance, the smaller number of parasites in the liver
stage reduces this risk. Interesting targets could be ascribed for
some of these TCP-1 and -4 dual-active compound including
MMV1578884 (REP3123) that targets Clostridium difﬁcile
methionyl-tRNA synthetase (metRS); to our knowledge there is
no aminoacyl-tRNA synthetase (aaRS) inhibitor in clinical antimalarial development, and structural differences between several
PfaaRS and their human counterparts leading to selective PfaaRS
inhibitors are encouraging43.
The involvement of protein and lipid kinases in key pathogen
functions have made inhibitors thereof a focus of drug design
strategies including those that affect multiple life cycle stages44.
Among the asexual stage active compounds, MMV1580482
(URMC-099) operates as a human MLK3 inhibitor and
MMV1593539 as a Staphylococcus aureus pyruvate kinase (PK1)
inhibitor, both of interest as kinase targets with a crystal structure
for PK1 are available (10.2210/pdb3KHD/pdb), which could
guide selectivity and optimization studies, if validated as the
target.
Importantly, our parallel screening approach on different life
cycle stages yielded compounds and chemical scaffolds that not
only have stage-speciﬁc asexual parasite activity but also selectively and speciﬁcally target the elusive gametocyte stages with
activity in mosquito transmission assays. This unbiased approach,
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in place of the paradigm where compounds are only proﬁled for
additional life cycle activity once asexual activity has been
established, conﬁrms the possibility of identifying gametocytespeciﬁc compounds7,8,10. Indeed, we identiﬁed several active
compounds that have no former documented antimalarial
activity, simply because they were previously not screened against
the correct life cycle stage of the parasite, where the relevant
biology being targeted was essential.
Our stringent proﬁling cascade additionally ensured a high
success rate in conﬁrming TBA and validates the use of orthogonal gametocytocidal screens4,10 as a primary ﬁlter in large-scale
screens. In addition, a linear correlation between gametocytocidal
and male gamete activity was present, which translated to oocyst
reduction. By evaluating both TRA and TBA, our data highlighted the importance of both parameters in evaluating SMFA
data. Notably, we showed a large reduction in TRA for some
compounds; the decreased number of oocysts carried by treated
mosquitoes will reduce transmission, as mosquito infection
intensity is critically important to the success of transmission45.
However, the additional decrease in oocyst prevalence (TBA)
implies that the majority of treated mosquitoes would not carry
parasites, which could have an epidemiological impact, in line
with World Health Organization-recommended vector control
interventions.
Gametocyte-targeted compounds would presumably target
divergent biological processes compared to asexual parasites46,
and this, in addition to the low parasite numbers in transmission
stages and non-proliferative nature of gametocytes, would reduce
the risk of resistance development. When used in combination
with a TCP-1 candidate, such TCP-5 targeted compounds could
protect the TCP-1 drug from resistance development. Alternatively, when used as a stand-alone drug, TCP-5 targeted
compounds could decrease the gametocyte burden in the human
population, which would be particularly important in preelimination settings as add-ons to enhance standard measures
of malaria control.
Our data indicate speciﬁc gametocyte-associated biological
processes worthy of further investigation, including two imidazoles (eberconazole, MMV1634492 and MMV1634491). The
antimalarial activity of eberconazole, a fungal ergosterol biosynthesis inhibitor47, has not been described before and may
point to an unexplored mode of action. We also identiﬁed ML324
with selective activity against early- and late-stage gametocytes,
similar to recent reports against immature gametocytes29. As a
known Pfjmj3 inhibitor, we show that ML324 potently kills male
gametes with conﬁrmed TBA and does so by preventing histone
demethylation, at least for H3K9me as heterochromatin mark 3
in gametocytes30. As a consequence, crucial genes required for the
maintenance of chromatin dynamics during gametocyte development are affected and a heterochromatic, silenced gene state is
maintained, preventing gamete formation. The distinct change in
the transcriptional programmes agrees with the effect of jumonji
histone demethylase inhibitors in Plasmodium spp.29, but contrast the effect seen with histone methyltransferase31 or the more
global changes of up to 60% of the transcriptome seen with
histone deacetylase inhibitors48. Gametocytes and male gametes
are therefore highly sensitive to changes in histone methylation
due to ML324 treatment, similar to what is seen for other Jmj
demethylase inhibitors29.
Lastly, our screens identiﬁed two compounds that are established inhibitors of MmpL3 in bacteria19–21. Albeit structurally
dissimilar, both compounds inhibit MmpL3 through interaction
with the protein pore section as indicated by co-crystallization
data49. A homologue for this protein is not detectable in the
Plasmodium genome, and our mechanistic data show that neither
is the PfNCR1 as MmpL3-family member a target, implying a
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non-MmpL3-associated mechanism of action. Rather, SQ109
pressure generates mutations in the PfVapA. The possibility that
this protein is not the direct target of SQ109 and only involved in
a SQ109 resistance mechanism cannot be excluded without further validation. However, if conﬁrmed as target, PfVapA could
present a druggable target in Plasmodium as has been implicated
for another antimalarial candidate class, triaminopyrimidine
(TAP)50, and could be explored51 similar to bedaquiline as
antitubercular targeting the F-type ATPase52. The SQ109 mutations are within the catalytic site, whereas those for TAP are not.
The more potent action of SQ109 on the non-proliferative differentiated P. falciparum gametocytes may indicate similar action
as for the non-proliferative and transmissible trypomastigotes of
Trypanosoma cruzi.32 MmpL3 is also absent in Trypanosoma and
Leishmania53 and SQ109’s activity is pleiotropic and includes
disruption of proton motor forces across membranes as an
uncoupler32. Such additional ionophore effects is reminiscent
again of additional actions seen for bedaquiline54. These
mechanisms are currently being investigated for P. falciparum,
including possible disruption of mitochondrial respiration46,55
and lipid metabolism/transport, which is essential to gametocytogenesis56 and oocyst development57.
Our data therefore provide an extensive data set of compounds
that could be repurposed or redirected for antimalarial development. One advantage of screening biologically active screening
collections such as the PRB is that they contain a large number of
compounds with well-described DMPK proﬁles and empirically
determined physical characteristics and that they could progress
rapidly through the drug discovery pipeline. Importantly, frontloading screening efforts with biologically active compounds also
point towards proteins that can be targeted in multiple parasite
life cycle stages.
Methods
Ethics statement. This work holds ethical approval from the University of Pretoria Health Sciences Ethics Committee (506/2018), University of Cape Town:
AEC017/026, University of the Witwatersrand Human Research Ethics Committee
(M130569) and Animal Ethics Committee (20190701-7O), CSIR Research Ethics
Committee (Ref 10/2011) and Scripps Research’s Normal Blood Donor Service
(NBDS), with approval under IRB Number 125933.
Parasite culturing. P. falciparum asexual parasites were cultured in vitro from
drug-sensitive strain NF54 (PfNF54), drug-resistant strain Dd2 (PfDd2, chloroquine, pyrimethamine and meﬂoquine resistant) and the luciferase reporter line
NF54-Pfs16-GFP-Luc (kind gift from David Fidock, Columbia University, USA)58
were used for the various downstream analyses. Gametocytogenesis was induced
from asexual NF54-background parasites as described4.
Asexual blood stage screening
Parasite lactate dehydrogenase (pLDH) assay. The asexual blood stage antiplasmodial activity was assessed on NF54 P. falciparum using the pLDH assay59,60.
Initially, all compounds were screened on two separate occasions by seeding ringstage cultures (1% haematocrit, 2% parasitaemia) in 96-well plates and adding
compounds at two concentrations only (2 and 20 µM), and survival was determined after 72 h under an appropriate atmosphere (4% CO2, 3% O2 and 93% N2)
at 37 °C, before survival was determined colorimetrically at 620 nm. The antiplasmodial IC50 was determined for suitably active compounds under the same
culture conditions as the single-point screens. Chloroquine and artesunate were
used as control compounds for all the antiplasmodial assays.
SYBR green I assay. Antiplasmodial activity on drug-resistant Dd2 P. falciparum
was determined with SYBR Green I ﬂuorescence13. Brieﬂy, parasite suspension
(0.3% parasitaemia, 2.5% haematocrit) was dispensed into 1536-well black, clear
bottom plates with pre-spotted compounds using a MultiFloTM Microplate dispenser (BioTek) at a volume of 8 μL/well. The plates were incubated at 37 °C for 72
h in a low-oxygen atmosphere, after which 10× SYBR Green I (Invitrogen) in Lysis
buffer (20 mM Tris/HCl, 5 mM EDTA, 0.16% (w/v) saponin, 1.6% (v/v) Triton X)
was added using MultiFloTM Microplate dispenser (BioTek) at a volume of 2 μL/
well. The plates were incubated in the dark at room temperature (RT) for 24 h.
P. falciparum proliferation was assessed by measuring the ﬂuorescence from the
bottom of the plates by using the EnVision® Multilabel Reader (PerkinElmer)
(485 nm excitation, 530 nm emission). IC50 values were determined in CDD vault
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(https://www.collaborativedrug.com/) normalized to maximum and minimum
inhibition levels for the positive (Artemisinin, 5 μM) and negative (dimethyl
sulfoxide (DMSO)) control wells.
Gametocyte screening4
PrestoBlue® ﬂuorescence assay. Stage IV/V gametocyte cultures (PfNF54, 2%
gametocytaemia, 5% haematocrit, 100 μL/well) were seeded with compounds (in
DMSO) and incubated at 37 °C for 48 h under hypoxic conditions, stationary, after
which 10 μL of PrestoBlue® reagent was added to each well and incubated at 37 °C
for 2 h. Supernatant (70 μL) was transferred to a clean 96-well plate and ﬂuorescence was detected at 612 nm. Dihydroartemisinin (DHA) was used as positive kill
control.
ATP bioluminescence assay. Stage IV/V PfNF54 gametocyte cultures were enriched
with density gradients4 and 30,000 gametocytes were seeded into 96-well plates in
the presence of compound and incubated for 24 h at 37 °C. ATP levels were
determined with a Promega BacTiter Glo Bioluminescence system4. DHA or
methylene blue (MB) were used as positive kill control.
Luciferase reporter assay. Stage IV/V gametocytes were produced from the NF54pfs16-GFP-Luc line58 seeded at 2% gametocytaemia and 2% haematocrit with
compounds (in DMSO) and incubated for 48 h under hypoxic conditions (stationary) at 37 °C. Luciferase activity was determined in 30 μL parasite lysates by
adding 30 μL luciferin substrate (Promega Luciferase Assay System) at RT and
detection of resultant bioluminescence at an integration constant of 10 s was
performed with a GloMax®-Multi+ Detection System with Instinct® Software4.
DHA, MB and MMV39004861 were used as positive drug controls and IC50 was
determined with non-linear curve ﬁtting (GraphPad Prism 6) normalized to
maximum and minimum inhibition (DMSO control wells).
P. berghei liver stage assay13. Compounds with potential causal prophylactic
activity were tested in HepG2-A16-CD81 cells seeded in 1536-well plates (Greiner
Bio) containing 50 nL of test and control compounds diluted into DMSO and
incubated for 24 h. Thereafter, P. berghei sporozoites (P. berghei ANKA GFP-LucSMcon) freshly obtained by dissecting salivary glands of infected A. stephensi
mosquitoes were added to each well at a density of 1 × 103 per well. The plates were
centrifuged for 5 min at 330 × g and incubated at 37 °C. Forty-eight hours post
infection, 2 μL of luciferin reagent (Promega BrightGlo) was added to each well,
and luciferase activity was detected using a Perkin Elmer Envision plate reader.
IC50 values were determined in CDD vault (https://www.collaborativedrug.com/)
normalized to maximum and minimum inhibition levels for the positive (GNF179,
5 μM) and negative (DMSO) control wells.
Cytotoxicity counter-screening
CHO toxicity screening. General cytotoxicity of the compounds was determined
using the 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide assay62
by exposing CHO cells for 48 h at 2 and 20 μM of each compound, and survival
was determined colorimetrically. Cells were seeded at a density of 106 cells/well in
200 µL of suitable medium and left overnight (O/N) to attach. After 24 h, medium
was gently aspirated from the culture plates, replaced with 200 µL of fresh medium
containing the compounds and incubated for a further 48 h. Emetine was used as
the control compound for cytotoxicity assessment.
HepG2 toxicity screening. Hepatocellular carcinoma line (HepG2-A16-CD81) was
seeded as above for the sporozoite liver stage assay but in the absence of sporozoites. HepG2 toxicity measurements was performed by adding Promega CellTiterGlo® (2 μL) followed by luminescence measurement. Curve ﬁtting was done as
described above using puromycin (25 μM) as a positive control and DMSO as
negative control wells.
Chemical clustering. Drug classes and biological pathways/protein targets were
identiﬁed based on text and structure searches (PubChem, DrugBank and SciFinder), and chemical space analysis was performed with StarDrop v 6.6 (https://
www.optibrium.com/stardrop/) based on structure similarities. The launched drug
space was generated from the data ﬁle available within the Stardrop software. The
antimalarial drug space was generated using marketed antimalarial drugs and
compounds undergoing clinical trials. The connectivity network was constructed
by clustering the compounds using the FragFP descriptor (Tanimoto similarity
index >0.50) in OSIRIS DataWarrior v 5.0.0 (www.openmolecules.org).
Male gamete exﬂagellation inhibition assay (EIA)63. The EIA was performed as
described63 on >95% stage V gametocytes, resuspended in 30 µL of ookinete
medium (culture media supplemented with 100 µM xanthurenic acid and 20%
(v/v) human serum, A+ male). For the carry-over experiment, mature stage V
gametocytes were treated with 2 μM of each compound for 48 h prior to induction
of exﬂagellation in the presence of compound. In the washout format, the same was
done but drug washed out before exﬂagellation was induced. In the direct format,
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drug (2 μM) was only added during induction of exﬂagellation in the ookinete
medium. Exﬂagellating centres were evaluated on 10 µL activated culture settled in
a Neubauer chamber at RT. Movement was recorded by video microscopy (Carl
Zeiss NT 6V/10W Stab microscope with a MicroCapture camera, ×10 magniﬁcation) and semi-automatically quantiﬁed from 15 videos of 8–10 s each (captured at
random locations) between 15 and 22.5 min after incubation.
Mosquito rearing and SMFA. A. coluzzii mosquitoes (G3 colony, species conﬁrmed in refs. 64,65) were reared under biosafety level 2 insectary conditions (80%
humidity, 25 °C, 12 h day/night cycle with 45 min dusk/dawn transitions66) on a
10% (w/v) sucrose solution diet supplemented with 0.05% 4-aminobenzoic acid.
SMFA was conducted using glass feeders (covered with cow intestine/sausage
casing to form a membrane) on top of feeding cups (350 mL), maintained at 37 °C.
A mature stage V gametocyte culture (1.5–2.5% gametocytaemia, 50% haematocrit
in A+ male serum with fresh erythrocytes) was functionally evaluated for male
gamete exﬂagellation and male:female ratio of 1:3 conﬁrmed before proceeding
with feeding. The gametocyte culture was either untreated or treated with 2 μM of
each compound 48 h. Per glass feeder, 1 mL of the gametocyte culture was added.
Each cup contained 25 unfed (2–3 h starvation) A. coluzzii females (5–7 days old),
which were allowed to feed in the dark for 40 min. All unfed or partially fed
mosquitoes were removed, and remaining females were housed as above for
8–10 days. Mosquitoes were dissected to remove midguts, which were rinsed in
phosphate-buffered saline (PBS) and placed into 0.1% (v/v) mercurochrome for
8–10 min and oocysts counted under bright ﬁeld illumination at ×20–×40 magniﬁcation. The percentage of block in transmission (reduction in prevalence) and
percentage of reduction in number of oocysts (intensity) were calculated after
normalizing to the control untreated sample. TBA (%TBA: CpCpTp *100, where
p: oocyst prevalence, C: control and T: treated) and TRA (%TRA: CiCiTi *100, where
i: oocyst number (intensity), C: control and T: treated)67 were determined. Each
biological replicated experiment included two technical repeats (two feeding cups
per compound), and this was repeated for at least three independent biological
experiments per compound. Non-parametric T test (Mann–Whitney) was applied
(GraphPad Prism 8.3.0) for statistical analysis.
Endectocide evaluation. Selected compounds were evaluated for endectocidal
activity by using SMFA as above but with 2 μM of each compound in cow blood
(100 μL) at 37 °C for 35 min feeds. Each 350 mL feeding cup contained 30, 4 h
starved and 2–4-day-old A. coluzzii females. Fully fed or partially fed females were
retained for daily monitoring of mortality under standard insectary rearing conditions, for up to 4 days post treatment. Ivermectin (1 μM) (Virbac, SA) and
DMSO (0.02% (v/v)) was used as controls. Between three and ﬁve independent
replicates were performed per compound.
Histone methylation detection. Late-stage gametocytes were treated with ML324
(5 µM) for 24 h after which histones were extracted from gametocytes for dot blots
and enriched as described before68. Sampled gametocytes were released from host
erythrocytes using 0.06% (w/v) saponin in PBS. The isolated gametocytes were
washed in PBS to remove residual erythrocyte debris. Nuclei were isolated using a
hypotonic lysis buffer (10 mM Tris HCl, pH 8.0, 3 mM MgCl2, 0.25 M sucrose, 0.2%
(v/v) Nonidet P-40) with a protease inhibitor (PI) cocktail and then collected by
centrifugation for 10 min at 500 × g and 4 °C. This step was repeated and nuclei
were washed in the same buffer lacking Nonidet P-40 and ﬁnally pelleted nuclei
were resuspended in a 10 mM Tris buffer (pH 8.0) containing 0.8 M NaCl, 1 mM
EDTA and a PI cocktail. Resuspended nuclei were incubated on ice for 10 min and
then collected through centrifugation at 500 × g for 5 min at 4 °C. Histones were
isolated by acid extraction in 0.25 M HCl with rotation at 4 °C O/N. The acidsoluble protein-containing supernatant was retained after centrifugation at
11,000 × g for 30 min. This was mixed with an equal volume of 20% (v/v) trichloroacetic acid and incubated on ice for 15 min, with the pellet collected by
centrifugation at 12,000 × g. The pellet was washed in acetone, collected again at
12,000 × g for 15 min and then reconstituted in dddH2O. The histone-enriched
supernatant was retained following centrifugation at 5000 × g for 2 min. The isolated
histones were quantitatively spotted onto nitrocellulose membranes in technical
triplicate. The membranes were blocked in TBS-T (50 mM Tris pH 7.5, 150 mM
NaCl, 0.1% (v/v) Tween) containing 5% (w/v) blotting-grade blocker (Bio-Rad) for
1 h and probed O/N with anti-H3K9me330 antibody (Abcam ab8898, 1:10,000),
anti-H3K9ac68 (Abcam ab4441, 1:10,000) and anti-H3 core30 (Abcam ab1791,
1:10,000) with antibody dilutions prepared in TBS-T. Membranes were then
incubated in goat anti-rabbit horseradish peroxidase-conjugated secondary antibody
(Abcam ab6721, 1:10,000) and visualized using Pierce SuperSignal West Pico PLUS
Chemiluminescent Substrate. Relative abundance units (n = 3, ±S.E.) for paired
treated and vehicle control samples were calculated using Image J 1.53a.
DNA microarrays of ML324-treated parasites. DNA microarrays (60-mer,
Agilent Technologies, USA) based on the full P. falciparum genome69 that included
5441 annotated transcripts46,70, were performed as before46. P. falciparum NF54
(1–3% gametocytaemia, 4% haematocrit in replicates, stage II/III gametocytes) was
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treated with 5 µM ML324 (Sigma-Aldrich, SA) for 24 h. Gametocytes were isolated
with 0.01% (w/v) saponin and total RNA was isolated using a combination of
TRIzol (Sigma-Aldrich, USA) treatment and phenol–chloroform extraction as
described before46. In all, 2.5–8 µg of the RNA was used to synthesize cDNA for
each sample (untreated and ML324-treated gametocytes) and dye-coupled to Cy5
(GE Healthcare, USA) and hybridized to the array with an equal amount (≥350 ng)
of Cy3-labelled (GE Healthcare, USA) reference cDNA (reference pool containing
cDNA from each gametocyte sample and mixed stage 3D7 asexual parasites). The
slides were scanned (5 µm resolution, at wavelengths of 532 nm and 633 nm for
Cy3 and Cy5, respectively) using an Agilent SureScan G2600D scanner. Agilent
Feature Extractor Software (v 11.5.1.1) was used to extract normalized signal
intensities according to the GE2_1100_Jul11_no_spikein protocol69. Robust-spline
within-slide and G-quantile between-slide normalization of array data was performed using the limma and marray packages in R (v3.2.3, www.r-project.org) with
log2-transformed expression values (log2 Cy5/Cy3) obtained from the ﬁtted linear
model. Genes with log2-transformed FCs (log2 FC) ≥ 0.5 in either direction were
deﬁned as differentially expressed in treated gametocytes. Differentially expressed
genes were visualized using TIGR MeV (v4.9.0, www.tm4.org) and functionally
classiﬁed by gene ontology (GO) enrichment analyses (biological processes,
p values ≤ 0.05) in PlasmoDB (v46, www.plasmodb.org). The full data set is
available in GEO with accession number GSE157420. GO analysis was performed
with the GO enrichment tool in PlasmoDB with a p value cut-off of 0.01 on the
level of biological process.

PfNCR1 cross-resistance analysis. Concentration–response curves with
MMV687273 (SQ109) were determined using a parasite clone in which the
expression of PfNCR1 is regulated by anhydrotetracycline (aTc)33. aTc (500 nM)
was removed by washing synchronous young ring-stage parasites three times for
10 min in culture media. To a portion of the parasite culture, 500 nM aTc was
added back. Parasites with 500 nM aTc or without aTc were diluted to a parasitaemia of 1.1% and incubated with compounds diluted in DMSO. The concentration of DMSO was kept constant at 0.1% (v/v). The PfNCR1-speciﬁc
compound MMV009108 was used as a positive control. Parasitaemias of acridine
orange-stained parasites were measured on a BD FACS Canto after 72 h and in
technical triplicate for each compound dilution. Data were processed using
GraphPad Prism 8.3.0 and ﬁt with nonlinear regression analysis.

Mutant generation and whole-genome sequencing and analysis of SQ109resistant parasites. P. falciparum clonal line 3D7-A10 (Saint Louis)71 was cultured at 2% haematocrit in O+ erythrocytes in RPMI supplemented with 0.5%
(w/v) Albumax II. Cultures were grown statically in 5% O2, 5% CO2 and 90% N2.
To generate resistant parasites, 3D7-A10 cultures were exposed to increasing
concentrations of SQ109. Parasites that returned after selection were cloned by
limiting dilution. Growth inhibition assays were performed in 200 μL volumes and
growth was quantiﬁed using Pico Green (at a 1:200 dilution; Life Technologies).
Pico Green ﬂuorescence was quantiﬁed using the ﬂuorescein ﬁlter set on an
EnVision Multilabel Platereader (Perkin Elmer). Growth assays commenced with
synchronized ring-stage parasites at 0.5% parasitaemia and growth was measured
after 72 h. EC50 values were calculated by ﬁtting a non-linear curve using the
expression Parasite Proliferation = ymin + ymax/(1 + [(drug concentration)/EC50]
b), where y is parasite proliferation and b is a ﬁtted constant.
Sequencing libraries were prepared from DNA extracted from the mutant and
parental cell lines with the Nextera XT Kit (Illumina), using the standard dual
index protocol. These were sequenced on the Illumina HiSeq 2500 in Rapid Run
mode, with an average read length of 100 base pairs. Reads were aligned to the
P. falciparum 3D7 reference genome (PlasmoDB v. 13.0)51, with single-nucleotide
variants (SNVs) and insertion/deletions called with the Genome Analysis Toolkit’s
HaplotypeCaller72–74. SNVs were removed if they met the following criteria:
ReadPosRankSum >8.0 or <−8.0, QUAL < 500, Quality by Depth <2, Mapping
Quality Rank Sum <−12.5, and ﬁltered depth <7. Mutations where read coverage
was <5 and/or where mixed-read ratios were >0.2 (reference/total reads) across all
samples were removed. Variants were annotated using SnpEff75. Variants present
in the resistant clones but not in the parent clone were identiﬁed. Since all parasite
lines were cloned before sequencing, only homozygous variant calls were retained.
Sequencing ﬁles were deposited in the National Center for Biotechnology
Information Sequence Read Archive database with accession code PRJNA659232.
Mutations in the V-type H+-ATPase subunit A (PF3D7_1311900) were conﬁrmed
by direct sequencing.

Data analysis. Assay platforms’ reproducibility was evaluated by Z’-factors
(Supplementary Data 1), and data are from a minimum of three independent
biological repeats as indicated. Statistical evaluation was performed with paired,
two-tailed t test for most assays, non-parametric t test (Mann–Whitney) was
applied for the SMFA data (GraphPad Prism 8.3.0) and Fisher’s exact two-tailed
test for GO annotations. Supra-hexagonal maps were generated in Rstudio 1.1.456
with the RColorBrewer R package.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
The authors declare that all relevant data supporting the ﬁndings of this study are
available within the paper and provided as Supplementary Data ﬁles (Files 1–4),
supplementary ﬁgures (Figs. 1–8) and supplementary tables (Tables 1–3) are included.
Transcriptome data is available from GEO (accession code GSE157420), whole-genome
sequencing data from NCBI Sequence Read Archive (PRJNA659232) and structural data
from Swiss Model Repository (Q76NM6). Source data are provided with this paper.

Code availability
Codes used to analyse data are available at GitHub (https://github.com/Ash-bot/Beehiveinhibition-plots).
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